熱門資訊> 正文
PharmaCyte Biotech宣布对MYMD战略投资700万美元
2024-05-21 21:16
- PharmaCyte Biotech (NASDAQ:PMCB) announced a $7 million investment in MyMD Pharmaceuticals (NASDAQ:MYMD), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions.
- PharmaCyte’s investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.
- Source: Press Release
More on MyMD Pharmaceuticals, PharmaCyte Biotech, Inc., etc.
- Financial information for MyMD Pharmaceuticals
- Financial information for PharmaCyte Biotech, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
